Association of fibroblast growth factor-23 with arterial stiffness in the Multi-Ethnic Study of Atherosclerosis.
BACKGROUND
Serum fibroblast growth factor-23 (FGF-23) is associated with cardiovascular disease (CVD), yet the mechanisms remain uncertain. Our objective was to determine whether higher FGF-23 concentrations are associated with arterial stiffness.


METHODS
In this cross-sectional study, serum FGF-23 concentrations were measured in 5977 participants without known CVD in the Multi-Ethnic Study of Atherosclerosis. The primary outcomes of interest were large (LAE) and small artery elasticity (SAE), pulse pressure and ankle-brachial index (ABI) > 1.30. LAE and SAE were measured by pulse contour analysis of the radial artery. Pulse pressure was measured with an automated sphygmomanometer using the average of two resting blood pressure measurements. ABI was calculated as the ratio of the ankle and brachial systolic blood pressures.


RESULTS
Serum FGF-23 concentrations were not significantly associated with LAE [relative difference (RD) per doubling: 0%; 95% confidence interval (CI): -2-1%], SAE (RD per doubling: 0%; 95% CI: -3-2%), pulse pressure (β per doubling: 0.44; 95% CI: -0.31-1.19), or a high ABI (odds ratio per doubling: 1.14; 95% CI: 0.84-1.55). Findings were similar irrespective of chronic kidney disease status.


CONCLUSIONS
Higher serum FGF-23 concentrations are not associated with arterial stiffness, as measured by pulse pressure, LAE, SAE or high ABI, in a community-based population without CVD.
Division of General Internal Medicine, San Francisco VA Medical Center, University of California, San Francisco, CA, USA.
Jeffrey J
JJ
Hsu
Department of Biostatistics, University of Washington, Seattle, WA, USA.
Ronit
R
Katz
Division of Nephrology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Joachim H
JH
Ix
Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA, USA.
Ian H
IH
de Boer
Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA, USA.
Bryan
B
Kestenbaum
Division of General Internal Medicine, San Francisco VA Medical Center, University of California, San Francisco, CA, USA.
Michael G
MG
Shlipak
D000368:Aged; D000369:Aged, 80 and over; D055109:Ankle Brachial Index; D050197:Atherosclerosis / Q000097:blood / Q000208:ethnology / Q000503:physiopathology*; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000502:physiology; D003124:Colorimetry; D003430:Cross-Sectional Studies; D005006:Ethnicity; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D007118:Immunoassay; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance; D015995:Prevalence; D011379:Prognosis; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000208:ethnology; D012189:Retrospective Studies; D014481:United States / Q000453:epidemiology; D059289:Vascular Stiffness / Q000502:physiology*
D015415:Biomarkers; C000717427:FGF23 protein, human; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23
ABI; FGF-23; arterial elasticity; arterial stiffness; pulse pressure